XENE Xenon Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: XENE

Price (delayed)

$43.75

Market cap

$3.3B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.73

Enterprise value

$3.16B

Xenon is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. The Company is advancing a novel product pipeline of ...

Highlights
The company's equity rose by 46% QoQ and by 29% YoY
The quick ratio has contracted by 10% YoY but it has grown by 10% from the previous quarter
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY
The company's revenue has shrunk by 100% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.xenon-pharma.com
Peers: PTCT ATNM

Key stats

What are the main financial stats of XENE
Market
Shares outstanding
75.43M
Market cap
$3.3B
Enterprise value
$3.16B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$182.69M
EBITDA
-$179.14M
Free cash flow
-$150.94M
Per share
EPS
-$2.73
Free cash flow per share
-$2.26
Book value per share
$14.18
Revenue per share
$0
TBVPS
$14.42
Balance sheet
Total assets
$964.8M
Total liabilities
$36.88M
Debt
$10.9M
Equity
$927.92M
Working capital
$617.69M
Liquidity
Debt to equity
0.01
Current ratio
23.65
Quick ratio
23.43
Net debt/EBITDA
0.77
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-24%
Return on equity
-25.2%
Return on invested capital
-28.1%
Return on capital employed
-19.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

XENE stock price

How has the Xenon Pharmaceuticals stock price performed over time
Intraday
1.74%
1 week
8.02%
1 month
5.93%
1 year
7.28%
YTD
-5.02%
QTD
1.63%

Financial performance

How have Xenon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$214.05M
Net income
-$182.39M
Gross margin
N/A
Net margin
N/A
Xenon Pharmaceuticals's gross profit has plunged by 100% YoY
The company's revenue has shrunk by 100% YoY
The operating income has dropped by 66% year-on-year and by 5% since the previous quarter
The net income has declined by 45% year-on-year and by 4.2% since the previous quarter

Growth

What is Xenon Pharmaceuticals's growth rate over time

Valuation

What is Xenon Pharmaceuticals stock price valuation
P/E
N/A
P/B
3.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 33% YoY and by 3% QoQ
The company's equity rose by 46% QoQ and by 29% YoY
XENE's price to book (P/B) is 9% lower than its last 4 quarters average of 3.4 but 6% higher than its 5-year quarterly average of 2.9
The company's revenue has shrunk by 100% YoY

Efficiency

How efficient is Xenon Pharmaceuticals business performance
Xenon Pharmaceuticals's return on equity has decreased by 42% YoY but it has increased by 3.1% QoQ
Xenon Pharmaceuticals's return on assets has decreased by 39% YoY but it has increased by 2.8% QoQ
XENE's return on invested capital is down by 25% year-on-year

Dividends

What is XENE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XENE.

Financial health

How did Xenon Pharmaceuticals financials performed over time
The total assets rose by 44% since the previous quarter and by 28% year-on-year
XENE's total liabilities is up by 13% year-on-year and by 7% since the previous quarter
XENE's debt is 99% smaller than its equity
The company's debt to equity has shrunk by 50% QoQ
The company's equity rose by 46% QoQ and by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.